Wang Siheng, Cai Chang, Shen Yingbo, Sun Chengtao, Shi Qingxin, Wu Ningjun, Zheng Shufang, Qian Jiao, Zhang Rong, Zhou Hongwei
Clinical Microbiology Laboratory, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
China Australia Joint Laboratory for Animal Health Big Data Analytics, College of Animal Science and Technology, Zhejiang Agricultural and Forestry University, Hangzhou, China.
Front Microbiol. 2021 Aug 19;12:729900. doi: 10.3389/fmicb.2021.729900. eCollection 2021.
Contezolid is a novel oxazolidinone, which exhibits potent activity against gram-positive bacteria, including methicillin-resistant (MRSA), vancomycin-resistant (VRE), and penicillin-resistant (PRSP). In this study, the activity of contezolid was compared with linezolid (LZD), tigecycline (TGC), teicoplanin (TEC), vancomycin (VA), daptomycin (DAP), and florfenicol (FFC) against MRSA and VRE strains isolated from China. Contezolid revealed considerable activity against MRSA and VRE isolates with MIC values of 0.5 and 1.0 μg/mL, respectively. For VRE strains with different resistance genotypes, including vanA- and vanM-type strains, contezolid did not exhibit significantly differential antibacterial activity. Furthermore, the antimicrobial activity of contezolid is similar to or slightly better than that of linezolid against MRSA and VRE strains. Subsequently, the activity of contezolid was tested against strains carrying linezolid resistance genes, including carrying gene and carrying gene. The results showed that contezolid exhibited similar antimicrobial efficacy to linezolid against strains with linezolid resistance genes. In general, contezolid may have potential benefits to treat the infections caused by MRSA and VRE pathogens.
康替唑胺是一种新型恶唑烷酮类药物，对革兰氏阳性菌具有强大活性，包括耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）和耐青霉素肺炎链球菌（PRSP）。在本研究中，比较了康替唑胺与利奈唑胺（LZD）、替加环素（TGC）、替考拉宁（TEC）、万古霉素（VA）、达托霉素（DAP）和氟苯尼考（FFC）对从中国分离出的MRSA和VRE菌株的活性。康替唑胺对MRSA和VRE分离株显示出相当强的活性，其MIC值分别为0.5和1.0μg/mL。对于具有不同耐药基因型的VRE菌株，包括vanA和vanM型菌株，康替唑胺未表现出明显的抗菌活性差异。此外，康替唑胺对MRSA和VRE菌株的抗菌活性与利奈唑胺相似或略优于利奈唑胺。随后，测试了康替唑胺对携带利奈唑胺耐药基因的菌株的活性，包括携带 基因和携带 基因的菌株。结果表明，康替唑胺对有利奈唑胺耐药基因的菌株表现出与利奈唑胺相似的抗菌效果。总体而言，康替唑胺在治疗由MRSA和VRE病原体引起的感染方面可能具有潜在益处。
